We hypothesize that frailty in older individuals might underly low responses to the 23-valent polysaccharide pneumococcal vaccination (PPV23) that will be implemented in the National immunization program in autumn this year for elderly 73-79 years…
ID
Bron
Verkorte titel
Aandoening
not applicable
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Assess the relation of frailty in 73-79 years old male and female persons with antibody responses to both vaccine pneumococcal polysaccharide serotypes and the Influenza virus vaccine strains by measuring HI titers pre and 4-6 weeks post vaccination.
Achtergrond van het onderzoek
With ageing there is a decline in the functioning of the immune system, making older people more vulnerable for infections and resulting in a smaller boost of the immune system in response to vaccination. Since there is great heterogeneity in the rate at which immune function declines, it is important to identify elderly at risk for low vaccination responses and thus at higher risk for infection. We hypothesize that frailty in older individuals might underly low responses to the 23-valent polysaccharide pneumococcal vaccination (PPV23) that will be implemented in the National immunization program in autumn this year for elderly 73-79 years of age.
To study this hypothesis, we will capitalize on the infrastructure and data provided by the ongoing longitudinal Doetinchem Cohort Study (DCS) (NL63779.041.17), which includes available frailty data of all participants, to assess the immune response to PPV23 and the yearly Influenza vaccine in relation to frailty. In the DCS, persons originally 20-59 years of age at study start, have been followed for over 30 years (N>3700). Various frailty parameters have been assessed in these participants. Based on these, a frailty score (index) has been determined by using the most recent information on 36 frailty-related “health deficits”, i.e. specific (co)morbidities, tests of physical (dys)functioning and cognition . Because of these data the DCS provides a unique opportunity to get insight into factors contributing to vaccine immunogenicity in older persons. Recent data from a sub-cohort of the DCS aged 60-80 years revealed that lingering inflammation is associated with frailty. Therefore frailty may be linked to reduced immune function and vaccination responses.
Doel van het onderzoek
We hypothesize that frailty in older individuals might underly low responses to the 23-valent polysaccharide pneumococcal vaccination (PPV23) that will be implemented in the National immunization program in autumn this year for elderly 73-79 years of age.
Onderzoeksopzet
Visit T0 (-4 till 0 week pre vaccination); Visit T1 (4-6 weeks post vaccination); Visit T2 (10-11 months post vaccination); Visit T3 (22-24 months post vaccination)
Onderzoeksproduct en/of interventie
venapunction
Algemeen / deelnemers
Wetenschappers
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
• Participant in round 6 of the Doetinchem Cohort study and born between 1941-1947
• Willing to receive the PPV23 vaccine in 2020
• Have signed Informed Consent.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
• Having had a previous pneumococcal vaccination
• Known or suspected allergy to any of the vaccine components or having experienced a previous severe adverse reaction to any vaccine.
• Receipt of any high-dose (≥ 20 mg of prednisone daily or equivalent) daily corticosteroids (locally applied including inhaled steroids are acceptable) within 2 weeks of study entry.
• Repeated use of any high dose of corticosteroids (a dose of > 30 mg of prednisone or equivalent per day for multiple days) in the last month.
• Receipt of a recent organ- or bone marrow transplant during the last 5 years .
• Have an anatomical or functional asplenia.
• Receipt of blood products or immunoglobulin, within one month of the study entry.
• Known or suspected coagulation disorder that in the opinion of the investigator would contraindicate against receiving an intramuscular injection or undergo frequent blood sampling.
• Known to be positive for human immunodeficiency virus (HIV), and/or hepatitis C virus (HCV) and/or hepatitis B virus (HBV).
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Toelichting
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL8812 |
| Ander register | METC Utrecht : METC 20-510 |